US20130345147A1 - Prevention and treatment of ocular side effects with a cyclosporin - Google Patents
Prevention and treatment of ocular side effects with a cyclosporin Download PDFInfo
- Publication number
- US20130345147A1 US20130345147A1 US13/957,772 US201313957772A US2013345147A1 US 20130345147 A1 US20130345147 A1 US 20130345147A1 US 201313957772 A US201313957772 A US 201313957772A US 2013345147 A1 US2013345147 A1 US 2013345147A1
- Authority
- US
- United States
- Prior art keywords
- therapeutically active
- cyclosporin
- active agent
- keratoconjunctivitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OKOQVKDKTRGTOQ-JTKSZBOXSA-N [H][C@](C(=O)CCCCCC)(N(C)C(=O)C(NC(=O)[C@H](CC(C)C)NC)C(C)C)[C@]([H])(O)[C@]([H])(C)C/C=C/C Chemical compound [H][C@](C(=O)CCCCCC)(N(C)C(=O)C(NC(=O)[C@H](CC(C)C)NC)C(C)C)[C@]([H])(O)[C@]([H])(C)C/C=C/C OKOQVKDKTRGTOQ-JTKSZBOXSA-N 0.000 description 1
- RDHYTEHLFAGCRE-CZDNZVSQSA-N [H][C@]12[C@H](O)[C@]3(O)C[C@H](O)C(C)=C([C@@H](O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@]12O)C3(C)C Chemical compound [H][C@]12[C@H](O)[C@]3(O)C[C@H](O)C(C)=C([C@@H](O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@]12O)C3(C)C RDHYTEHLFAGCRE-CZDNZVSQSA-N 0.000 description 1
- WFHXICRGKCXQMK-QFDBFIRVSA-N [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)CC(OC(=O)[C@H](O)C(NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@]12OC(C)=O)C3(C)C.[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)CC(OC(=O)[C@H](O)[C@@H](NC(=O)OCC(C)C)C4=CC=CC=C4)C(C)=C([C@@H](O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@]12OC(C)=O)C3(C)C Chemical compound [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)CC(OC(=O)[C@H](O)C(NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@]12OC(C)=O)C3(C)C.[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)CC(OC(=O)[C@H](O)[C@@H](NC(=O)OCC(C)C)C4=CC=CC=C4)C(C)=C([C@@H](O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@]12OC(C)=O)C3(C)C WFHXICRGKCXQMK-QFDBFIRVSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- Patients undergoing treatment with certain therapeutically active agents can have certain ocular conditions as a result of that treatment.
- patients undergoing chemotherapy with a therapeutically active agent effective for treatment of a cancer often have ocular conditions as a result of that treatment.
- One embodiment is a method comprising administering a cyclosporin, an analog or derivative thereof, or a combination thereof, to an eye of a mammal in combination with administration of a therapeutically active agent to said mammal, said therapeutically active agent being an chemotherapy agent or an antiviral agent, wherein said method is effective in preventing or treating an ocular condition associated with the use of said therapeutically active agent.
- administering means administration of the therapeutically active agent to the mammal in any way that a therapeutically active agent may be administered.
- administration of the therapeutically active agent is not limited to the eye, but may include systemic administration via oral, intravenous, rectal, or other means; or administration locally to any part of the body by injection, implantation, topical administration, or other means.
- Administration of the therapeutically active agent need not exactly overlap in time with the administration of the cyclosporin, an analog or derivative thereof, or a combination thereof.
- the cyclosporin, analog or derivative thereof, or a combination thereof might be administered to a mammal before the mammal receives any of the therapeutically active agent to avoid the onset of the ocular condition.
- the cyclosporin, analog or derivative thereof, or a combination thereof might be administered after the mammal has begun to receive the therapeutically active agent.
- the cyclosporin, analog or derivative thereof, or a combination thereof might be administered after the mammal has ceased receiving the therapeutically active agent.
- Administration of the cyclosporin, analog or derivative thereof, or a combination thereof might also be simultaneous with the administration of the therapeutically active agent.
- any time relationship may exist between the mammal receiving the therapeutically active agent and the cyclosporin, analog or derivative thereof, or a combination thereof, provided that the use of the latter is reasonably related to treatment or prophylaxis of a condition associated with the former.
- composition which comprises both (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent when the agents are to be administered simultaneously.
- kits may be convenient to provide (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent in form of a kit.
- the agents may be packaged together.
- the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent may each be packaged in conventional pharmaceutical packaging such as boxes, jars, blister packs, vials, bottles, syringes etc., and the individually packaged components may then be combined to form a kit e.g. by the use of further packaging such as a box, or by joining up the individual packages.
- kit form the agents can be taken independently of one another, thus allowing the user freedom to decide the temporal relationship between his use of each of the agents.
- a cyclosporin, or an analog or derivative thereof, including cyclosporin A for the treatment of ocular conditions occurring in a person undergoing treatment with a therapeutically active agent for the treatment of cancer is contemplated. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of a chemotherapy agent.
- a cyclosporin or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an antiviral agent. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an antiviral agent.
- a cyclosporin or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an immunomodulator. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an immunomodulator.
- Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
- cyclosporins include cyclosporine b, cyclosporine D, cyclosporine G, which are well known in the art. Cyclosporin derivatives and analogs are also known in the art. For example, U.S. Pat. Nos. 6,254,860 and 6,350,442, incorporated by reference herein, illustrate several examples.
- nasolacrimal stenosis nasolacrimal stenosis, chemotherapy induced ocular toxicity, lacrimal duct stenosis, punctal stenosis, lacrimation, abnormal lacrimation (such as keratoconjunctivitis sicca), increased tearing, nasolacrimal blockage, keratitis, keratoconjunctivitis, conjunctivitis, or a combination thereof may be prevented or treated.
- Also contemplated is a method comprising administering cyclosporin A topically to the eye of a person, wherein docetaxel is also administered to said person, wherein said method is effective in preventing or treating an ocular condition associated with the administration of docetaxel.
- the ocular condition may be associated with any antiviral agent, the following
- the ocular condition may be associated with any chemotherapy agent, the following
- Derivatives of paclitaxel generally include the macrocycle shown below, where derivatives are formed at a hydroxyl moiety.
- Chemotherapeutic compounds incorporating this structure are thus contemplated.
- the structures of paclitaxel and docetaxel are shown below.
- the chemotherapy agent is docetaxel.
- the ocular condition may be associated with any immunomodulator, the following
- therapeutically active agents may cause lacrimal duct stenosis: docetaxel.
- therapeutically active agents may cause keratoconjunctivitis: Capecitabine.
- one or more of the ocular conditions disclosed herein may be associated with the following therapeutically active agents: abacavir sulfate, amantadine hydrochloride, amphotericin B, basiliximab, bexarotene, capecitabine, cetuximab, delavirdine mesylate, docetaxel, doxorubicin hydrochloride, enfuvirtide, epirubicin hydrochloride, erlotinib, fluorouracil, gefitinib, glatiramer acetate, imatinib mesylate, imiquimod, interferon alfa-2b, irinotecan hydrochloride, ivermectin, lamivudine, lamotrigine, leflunomide, mycophenolate mofetil, mycophenolate mofetil hydrochloride, nevirapine, oseltamivir phosphate, oxaliplatin, palivi
- the therapeutically active agent is administered in the usual manner known in the art for the condition being treated.
- a therapeutically active agent and cyclosporin A may be administered in a single composition.
- compositions are disclosed in the following patent applications, each of which is expressly incorporated by reference herein: U.S. patent application Ser. No. 11/181, 409, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 509, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 187, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 178, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 428, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/255,821, filed on Oct. 19, 2005; U.S. patent application Ser. No. 11/161,218, filed on Jul. 27, 2005; and U.S. Provisional Patent Application Ser. No. 60/727,684, filed on Oct. 17, 2005.
- cyclosporin A is administered in the form of Restasis®, available from Allergan, Inc.
- the cyclosporin A is administered twice a day as indicated on the package insert.
Abstract
Therapeutic methods are disclosed herein.
Description
- This continuation application claims priority to: U.S. Provisional Patent Application No. 60/596,709, filed on Oct. 14, 2005; U.S. Provisional Patent Application No. 60/597,431, filed on Nov. 30, 2005; U.S. Provisional Patent Application, No. 60/805,577, filed on Jun. 22, 2006; U.S. patent application Ser. No. 11/548,631, filed Oct. 11, 2006, now U.S. Pat. No. 7,745,400; U.S. patent application Ser. No. 12/825,116, filed Jun. 28, 2010, now U.S. Pat. No. 8,501,174; and co-pending U.S. patent application Ser. No. 13/957,722, filed Aug. 2, 2013, all of which are expressly incorporated by reference herein.
- Patients undergoing treatment with certain therapeutically active agents can have certain ocular conditions as a result of that treatment. In particular, patients undergoing chemotherapy with a therapeutically active agent effective for treatment of a cancer often have ocular conditions as a result of that treatment.
- One embodiment is a method comprising administering a cyclosporin, an analog or derivative thereof, or a combination thereof, to an eye of a mammal in combination with administration of a therapeutically active agent to said mammal, said therapeutically active agent being an chemotherapy agent or an antiviral agent, wherein said method is effective in preventing or treating an ocular condition associated with the use of said therapeutically active agent.
- “Administration of a therapeutically active agent to said mammal” means administration of the therapeutically active agent to the mammal in any way that a therapeutically active agent may be administered. Thus, administration of the therapeutically active agent is not limited to the eye, but may include systemic administration via oral, intravenous, rectal, or other means; or administration locally to any part of the body by injection, implantation, topical administration, or other means.
- Administration of the therapeutically active agent need not exactly overlap in time with the administration of the cyclosporin, an analog or derivative thereof, or a combination thereof. For example, the cyclosporin, analog or derivative thereof, or a combination thereof might be administered to a mammal before the mammal receives any of the therapeutically active agent to avoid the onset of the ocular condition. In another example, the cyclosporin, analog or derivative thereof, or a combination thereof, might be administered after the mammal has begun to receive the therapeutically active agent. In another example, the cyclosporin, analog or derivative thereof, or a combination thereof, might be administered after the mammal has ceased receiving the therapeutically active agent. Administration of the cyclosporin, analog or derivative thereof, or a combination thereof might also be simultaneous with the administration of the therapeutically active agent. Thus, any time relationship may exist between the mammal receiving the therapeutically active agent and the cyclosporin, analog or derivative thereof, or a combination thereof, provided that the use of the latter is reasonably related to treatment or prophylaxis of a condition associated with the former.
- It may be convenient to provide a single pharmaceutical composition which comprises both (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent when the agents are to be administered simultaneously.
- It may be convenient to provide (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent in form of a kit. For example, the agents may be packaged together. For example, (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent may each be packaged in conventional pharmaceutical packaging such as boxes, jars, blister packs, vials, bottles, syringes etc., and the individually packaged components may then be combined to form a kit e.g. by the use of further packaging such as a box, or by joining up the individual packages. When in kit form, the agents can be taken independently of one another, thus allowing the user freedom to decide the temporal relationship between his use of each of the agents.
- Use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person undergoing treatment with a therapeutically active agent for the treatment of cancer is contemplated. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of a chemotherapy agent.
- Also contemplated is use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an antiviral agent. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an antiviral agent.
- Also contemplated is use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an immunomodulator. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an immunomodulator.
- Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
- Other cyclosporins include cyclosporine b, cyclosporine D, cyclosporine G, which are well known in the art. Cyclosporin derivatives and analogs are also known in the art. For example, U.S. Pat. Nos. 6,254,860 and 6,350,442, incorporated by reference herein, illustrate several examples.
- The ocular conditions to be prevented or treated are well known in the art. In particular, nasolacrimal stenosis, chemotherapy induced ocular toxicity, lacrimal duct stenosis, punctal stenosis, lacrimation, abnormal lacrimation (such as keratoconjunctivitis sicca), increased tearing, nasolacrimal blockage, keratitis, keratoconjunctivitis, conjunctivitis, or a combination thereof may be prevented or treated.
- Also contemplated is a method comprising administering cyclosporin A topically to the eye of a person, wherein docetaxel is also administered to said person, wherein said method is effective in preventing or treating an ocular condition associated with the administration of docetaxel.
- Although the ocular condition may be associated with any antiviral agent, the following
- antiviral agents are contemplated in particular:
- Zalcitabine, and
- Rimantadine Hydrochloride.
- Although the ocular condition may be associated with any chemotherapy agent, the following
- chemotherapy agents are contemplated in particular:
- Paclitaxel and derivatives thereof, such as Docetaxel
- Doxorubicin Hydrochloride,
- Irinotecan Hydrochloride,
- Fluorouracil,
- Imatinib Mesylate, and
- Rituximab.
- Derivatives of paclitaxel generally include the macrocycle shown below, where derivatives are formed at a hydroxyl moiety.
- Chemotherapeutic compounds incorporating this structure are thus contemplated. For example, the structures of paclitaxel and docetaxel are shown below.
- In one embodiment, the chemotherapy agent is docetaxel.
- Although the ocular condition may be associated with any immunomodulator, the following
- immunomodulators are contemplated in particular:
- Interferon alfa-2b, Recombinant
- Mycophenolate Mofetil, and
- Mycophenolate Mofetil Hydrochloride.
- While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause lacrimal duct stenosis: docetaxel.
- While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause lacrimation:
- interferon alfa-2b, recombinant,
- doxorubicin hydrochloride,
- irinotecan hydrochloride,
- fluorouracil,
- docetaxel, and
- zalcitabine.
- While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause abnormal lacrimation:
- mycophenolate motefil,
- mycophenolate motefil hydrochloride,
- imatinib mesylate,
- ritumixab, and
- rimantadine hydrochloride.
- While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause keratitis:
- Amantadine Hydrochloride,
- Erlotinib,
- Bexarotene, and
- Voriconazole.
- While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause keratoconjunctivitis: Capecitabine.
- While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause conjunctivitis:
- Risedronate Sodium,
- Leflunomide,
- Mycophenolate Mofetil,
- Oxaliplatin,
- Cetuximab,
- Ribavirin,
- Rituximab,
- Basiliximab,
- Erlotinib,
- Capecitabine,
- Doxorubicin Hydrochloride,
- Imiquimod,
- Amphotericin B, liposomal,
- Zolpidem Tartrate,
- Glatiramer Acetate,
- Epirubicin Hydrochloride,
- Saquinavir,
- Enfuvirtide,
- Imatinib Mesylate,
- Gefitinib,
- Lamotrigine,
- Delavirdine Mesylate,
- Rituximab,
- Ivermectin,
- Palivizumab,
- Oseltamivir Phosphate,
- Bexarotene,
- Docetaxel,
- Abacavir Sulfate,
- Lamivudine,
- Zidovudine,
- Voriconazole,
- Nevirapine,
- Ribavirin, and
- Abacavir Sulfate.
- Additionally, one or more of the ocular conditions disclosed herein may be associated with the following therapeutically active agents: abacavir sulfate, amantadine hydrochloride, amphotericin B, basiliximab, bexarotene, capecitabine, cetuximab, delavirdine mesylate, docetaxel, doxorubicin hydrochloride, enfuvirtide, epirubicin hydrochloride, erlotinib, fluorouracil, gefitinib, glatiramer acetate, imatinib mesylate, imiquimod, interferon alfa-2b, irinotecan hydrochloride, ivermectin, lamivudine, lamotrigine, leflunomide, mycophenolate mofetil, mycophenolate mofetil hydrochloride, nevirapine, oseltamivir phosphate, oxaliplatin, palivizumab, ribavirin, rimantadine hydrochloride, risedronate sodium, rituximab, saquinavir, voriconazole, zalcitabine, zidovudine, and zolpidem tartrate.
- The therapeutically active agent is administered in the usual manner known in the art for the condition being treated.
- Alternatively, a therapeutically active agent and cyclosporin A may be administered in a single composition.
- Useful compositions are disclosed in the following patent applications, each of which is expressly incorporated by reference herein: U.S. patent application Ser. No. 11/181, 409, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 509, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 187, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 178, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 428, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/255,821, filed on Oct. 19, 2005; U.S. patent application Ser. No. 11/161,218, filed on Jul. 27, 2005; and U.S. Provisional Patent Application Ser. No. 60/727,684, filed on Oct. 17, 2005.
- In one embodiment, cyclosporin A is administered in the form of Restasis®, available from Allergan, Inc. The cyclosporin A is administered twice a day as indicated on the package insert.
- Although there has been hereinabove described pharmaceutical compositions for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not limited thereto. Accordingly, any and all modifications, variations, or equivalent arrangements, which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.
Claims (9)
1.-11. (canceled)
12. A method comprising administering an ophthalmically acceptable emulsion comprising cyclosporin A to a mammal before the mammal receives a therapeutically active agent, wherein the therapeutically active agent comprises paclitaxel, and wherein the method is effective in treating abnormal lacrimation.
13. The method of claim 12 , wherein the ophthalmically acceptable emulsion comprises cyclosporin A at a concentration of about 0.05%.
14. The method of claim 13 , wherein the ophthalmically acceptable emulsion further comprises castor oil, polysorbate 80, and high molecular weight co-polymers of acrylic acid and a long chain alkyl methacrylate cross-linked with allyl ethers of pentaerythritol.
15. The method of claim 13 , wherein the abnormal lacrimation is associated with keratoconjunctivitis.
16. The method of claim 13 , wherein the abnormal lacrimation is the result of keratoconjunctivitis.
17. The method of claim 15 , wherein the keratoconjunctivitis is associated with the therapeutically active agent.
18. The method of claim 16 , wherein the keratoconjunctivitis is associated with the therapeutically active agent.
19.-24. (canceled)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/957,772 US20130345147A1 (en) | 2005-10-14 | 2013-08-02 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/966,770 US20140011751A1 (en) | 2005-10-14 | 2013-08-14 | Prevention and treatment of ocular side effects with a cyclosporin |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59670905P | 2005-10-14 | 2005-10-14 | |
US59743105P | 2005-11-30 | 2005-11-30 | |
US80550906P | 2006-06-22 | 2006-06-22 | |
US80557706P | 2006-06-22 | 2006-06-22 | |
US11/548,631 US7745400B2 (en) | 2005-10-14 | 2006-10-11 | Prevention and treatment of ocular side effects with a cyclosporin |
US12/825,116 US8501174B2 (en) | 2005-10-14 | 2010-06-28 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/957,772 US20130345147A1 (en) | 2005-10-14 | 2013-08-02 | Prevention and treatment of ocular side effects with a cyclosporin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/825,116 Continuation US8501174B2 (en) | 2005-10-14 | 2010-06-28 | Prevention and treatment of ocular side effects with a cyclosporin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/966,770 Continuation US20140011751A1 (en) | 2005-10-14 | 2013-08-14 | Prevention and treatment of ocular side effects with a cyclosporin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130345147A1 true US20130345147A1 (en) | 2013-12-26 |
Family
ID=38263959
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/548,631 Active US7745400B2 (en) | 2005-10-14 | 2006-10-11 | Prevention and treatment of ocular side effects with a cyclosporin |
US12/825,116 Active 2027-06-08 US8501174B2 (en) | 2005-10-14 | 2010-06-28 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/957,722 Abandoned US20140030226A1 (en) | 2005-10-14 | 2013-08-02 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/957,772 Abandoned US20130345147A1 (en) | 2005-10-14 | 2013-08-02 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/957,796 Abandoned US20140038904A1 (en) | 2005-10-14 | 2013-08-02 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/966,744 Abandoned US20140010846A1 (en) | 2005-10-14 | 2013-08-14 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/966,770 Abandoned US20140011751A1 (en) | 2005-10-14 | 2013-08-14 | Prevention and treatment of ocular side effects with a cyclosporin |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/548,631 Active US7745400B2 (en) | 2005-10-14 | 2006-10-11 | Prevention and treatment of ocular side effects with a cyclosporin |
US12/825,116 Active 2027-06-08 US8501174B2 (en) | 2005-10-14 | 2010-06-28 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/957,722 Abandoned US20140030226A1 (en) | 2005-10-14 | 2013-08-02 | Prevention and treatment of ocular side effects with a cyclosporin |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/957,796 Abandoned US20140038904A1 (en) | 2005-10-14 | 2013-08-02 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/966,744 Abandoned US20140010846A1 (en) | 2005-10-14 | 2013-08-14 | Prevention and treatment of ocular side effects with a cyclosporin |
US13/966,770 Abandoned US20140011751A1 (en) | 2005-10-14 | 2013-08-14 | Prevention and treatment of ocular side effects with a cyclosporin |
Country Status (2)
Country | Link |
---|---|
US (7) | US7745400B2 (en) |
TW (1) | TW200735886A (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US20140011750A1 (en) * | 2005-10-14 | 2014-01-09 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
CA2701482C (en) | 2007-10-08 | 2018-10-23 | Lux Biosciences, Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
US20110009339A1 (en) * | 2009-04-14 | 2011-01-13 | Allergan, Inc | Method of treating blurred vision and other conditions of the eye with cyclosporin compositions |
EP2440185B1 (en) | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
GB201514328D0 (en) * | 2015-08-12 | 2015-09-23 | Sigmoid Pharma Ltd | Compositions |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030191179A1 (en) * | 1999-10-25 | 2003-10-09 | Supergen, Inc. | Methods for administration of paclitaxel |
US20050282734A1 (en) * | 1998-07-30 | 2005-12-22 | Kadima Tenshuk A | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
US20060018910A1 (en) * | 2004-07-16 | 2006-01-26 | Pfizer Inc | Combination treatment for non-hematologic malignancies |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2907460A1 (en) | 1978-03-07 | 1979-09-13 | Sandoz Ag | NEW RESORBABLE GALENIC COMPOSITIONS |
US4388229A (en) | 1981-11-02 | 1983-06-14 | Syntex (U.S.A.) Inc. | Contact lens rejuvenating solution |
US4533594A (en) | 1983-12-16 | 1985-08-06 | Porritts & Spencer | Batt-on-mesh felt employing polyurethane-coated multifilaments in the cross-machine direction |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
US4649047A (en) | 1985-03-19 | 1987-03-10 | University Of Georgia Research Foundation, Inc. | Ophthalmic treatment by topical administration of cyclosporin |
US4814323A (en) | 1986-03-25 | 1989-03-21 | Andrieu J M | Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus |
JP2577049B2 (en) | 1987-06-04 | 1997-01-29 | 三共株式会社 | Cyclosporine preparation |
KR920003601B1 (en) * | 1987-09-03 | 1992-05-04 | 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 | Ocular cyclosporin composition |
US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
HU201567B (en) | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
KR0148748B1 (en) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | A multiphase cyclosporin composition |
US6007840A (en) | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
US7081445B2 (en) | 1989-02-20 | 2006-07-25 | Novartis Ag | Cyclosporin galenic forms |
US4996193A (en) | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5294604A (en) | 1989-12-20 | 1994-03-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating ocular diseases by periocular administration of cyclosporine A or G |
CA2048302A1 (en) | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
MA22456A1 (en) | 1991-03-05 | 1992-10-01 | Procter & Gamble | PERSONAL CLEANING PRODUCT OF THE SOFT, STABLE LIQUID SOAP TYPE AND METHOD FOR THE PREPARATION THEREOF |
IL102236A0 (en) | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
WO1993023010A1 (en) | 1992-05-13 | 1993-11-25 | Sandoz Ltd. | Ophthalmic compositions containing a cyclosporin |
DK0589843T3 (en) | 1992-09-25 | 2002-04-02 | Novartis Ag | Cyclosporin-containing pharmaceutical preparations |
US20020107183A1 (en) | 1993-04-20 | 2002-08-08 | Monika Petszulat | Pharmaceutical preparations comprising cyclosporin for oral administration |
CH686761A5 (en) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Pharmaceutical formulations. |
US20020099067A1 (en) | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
DE4340781C3 (en) | 1993-11-30 | 2000-01-27 | Novartis Ag | Liquid preparations containing cyclosporin and process for their preparation |
US5891846A (en) | 1994-02-17 | 1999-04-06 | Shiseido Company, Ltd. | Cyclosporin-containing emulsion composition |
KR0146671B1 (en) | 1994-02-25 | 1998-08-17 | 김충환 | Cyclosporin-containing powder composition |
US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
US5827835A (en) | 1994-08-30 | 1998-10-27 | Alcon Laboratories, Inc. | Thermally-gelling emulsions |
CN1121238C (en) | 1994-11-03 | 2003-09-17 | 诺瓦蒂斯有限公司 | Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability and process for producing them |
KR0167613B1 (en) | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | Cyclosporin-containing soft capsule compositions |
US5834017A (en) | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5962019A (en) | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5827822A (en) | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
DE19544507B4 (en) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin containing preparations |
US6787306B1 (en) * | 1996-03-20 | 2004-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for detecting dihydropyrimidine dehydrogenase splicing mutations |
US5753166A (en) | 1996-04-29 | 1998-05-19 | Eastman Chemical Company | Process of making a non-circular cross-sectional fiber |
US5798333A (en) | 1996-09-17 | 1998-08-25 | Sherman; Bernard C. | Water-soluble concentrates containing cyclosporins |
SG115386A1 (en) | 1997-01-30 | 2005-10-28 | Novartis Ag | Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil |
FR2762843B1 (en) | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
NZ328751A (en) | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
EP1042341A1 (en) * | 1997-11-25 | 2000-10-11 | Protarga Inc. | Nucleoside analog compositions and uses thereof |
CA2313024C (en) | 1997-12-10 | 2008-06-03 | Severson, Mary L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
TWI241915B (en) | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
KR100336090B1 (en) | 1998-06-27 | 2002-05-27 | 윤승원 | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof |
DE19835906A1 (en) | 1998-08-07 | 2000-02-10 | Basf Ag | Process for the production of vinyl compounds |
MXPA01005884A (en) | 1998-12-11 | 2002-04-24 | Pharmasolutions Inc | Self-emulsifying compositions for drugs poorly soluble in water. |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
US6057289A (en) | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
WO2001032142A1 (en) | 1999-11-02 | 2001-05-10 | Cipla Limited | Cyclosporin formulation |
DE19958684A1 (en) * | 1999-12-06 | 2001-06-07 | Knoll Ag | Use of GD3 synthase inhibitors for the treatment of neuropathological disorders and methods for the identification of GD3 synthase inhibitors |
GB0007907D0 (en) | 2000-03-31 | 2000-05-17 | Merck Sharp & Dohme | Therapeutic agents |
DK1142566T3 (en) | 2000-04-07 | 2004-02-09 | Medidom Lab | Ophthalmological formulations based on cyclosporine, hyaluronic acid and polysorbate |
GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
CN1127955C (en) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | Medicine for treating immune relative disease of anterior chamber and surface of eye |
ES2236481T3 (en) * | 2001-01-16 | 2005-07-16 | Glaxo Group Limited | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINAMINE AND PACLITAXEL, CARBOPLATIN OR VINORELBINE FOR CANCER TREATMENT. |
AR033711A1 (en) | 2001-05-09 | 2004-01-07 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS |
US6656460B2 (en) | 2001-11-01 | 2003-12-02 | Yissum Research Development | Method and composition for dry eye treatment |
ITMI20012694A1 (en) | 2001-12-19 | 2003-06-19 | Remedia S R L | PHARMACEUTICAL COMPOSITION INCLUDING A DOUBLE OIL / WATER / OIL MICROEMULSION INCORPORATED IN A SOLID SUPPORT |
BR0215187A (en) | 2001-12-20 | 2004-11-16 | Bernard Charles Sherman | Pharmaceutical compositions comprising a cyclosporine, a hydrophilic surfactant and a lipophilic surfactant |
KR100441167B1 (en) | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | Composition of microemulsion preconcentrate |
KR20030065831A (en) | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | cyclosporin-containing sustained release pharmaceutical composition |
US20030225011A1 (en) * | 2002-05-31 | 2003-12-04 | Samuel David | Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease |
GB2391473B (en) | 2002-08-02 | 2004-07-07 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
GB2391471B (en) | 2002-08-02 | 2005-05-04 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
GB2391472B (en) | 2002-08-02 | 2004-12-08 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
AU2003277424A1 (en) * | 2002-10-17 | 2004-05-04 | New York University | Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US20040185068A1 (en) | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
US20050196370A1 (en) | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
US20050043258A1 (en) * | 2003-03-26 | 2005-02-24 | Genteric, Inc. | Methods of treating xerostomia and xerophthalmia |
EP1624858B1 (en) | 2003-04-09 | 2018-06-06 | Rutgers, the State University of New Jersey | Novel encochleation methods |
US7083802B2 (en) | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
AR047988A1 (en) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | ANTI -OPLASTIC COMBINATIONS OF CCI-779 AND RITUXIMAB |
EP1933832A2 (en) * | 2005-06-23 | 2008-06-25 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
WO2008000085A1 (en) | 2006-06-30 | 2008-01-03 | The University Of Western Ontario | Process for producing a concrete additive from an agricultural residue |
US8536190B2 (en) * | 2007-01-30 | 2013-09-17 | Allergan, Inc. | Treating unwanted ocular conditions using an ascomycin macrolactam |
-
2006
- 2006-10-11 US US11/548,631 patent/US7745400B2/en active Active
- 2006-10-14 TW TW095137960A patent/TW200735886A/en unknown
-
2010
- 2010-06-28 US US12/825,116 patent/US8501174B2/en active Active
-
2013
- 2013-08-02 US US13/957,722 patent/US20140030226A1/en not_active Abandoned
- 2013-08-02 US US13/957,772 patent/US20130345147A1/en not_active Abandoned
- 2013-08-02 US US13/957,796 patent/US20140038904A1/en not_active Abandoned
- 2013-08-14 US US13/966,744 patent/US20140010846A1/en not_active Abandoned
- 2013-08-14 US US13/966,770 patent/US20140011751A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050282734A1 (en) * | 1998-07-30 | 2005-12-22 | Kadima Tenshuk A | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
US20030191179A1 (en) * | 1999-10-25 | 2003-10-09 | Supergen, Inc. | Methods for administration of paclitaxel |
US20060018910A1 (en) * | 2004-07-16 | 2006-01-26 | Pfizer Inc | Combination treatment for non-hematologic malignancies |
Non-Patent Citations (2)
Title |
---|
Akpek et al. A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant Atopic Keratoconjunctivitis. Ophthalmology. March 2004, Volume 111, Number 3, pages 476-482. * |
Schmid et al. Update on Ocular Complications of Systemic Cancer Chemotherapy. Survey Of Ophthalmology. January-February 2006, Volume 51, Number 1, pages 19-40. * |
Also Published As
Publication number | Publication date |
---|---|
TW200735886A (en) | 2007-10-01 |
US20100266622A1 (en) | 2010-10-21 |
US20140010846A1 (en) | 2014-01-09 |
US20070167358A1 (en) | 2007-07-19 |
US8501174B2 (en) | 2013-08-06 |
US20140038904A1 (en) | 2014-02-06 |
US20140011751A1 (en) | 2014-01-09 |
US7745400B2 (en) | 2010-06-29 |
US20140030226A1 (en) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130345147A1 (en) | Prevention and treatment of ocular side effects with a cyclosporin | |
US9603895B2 (en) | Cyclosporin analogues for preventing or treating hepatitis C infection | |
US8481483B2 (en) | Cyclosporin analogues | |
US8623814B2 (en) | Antiviral agents | |
US8367053B2 (en) | Cyclosporin analogues | |
NO334908B1 (en) | Pharmaceutical preparation for the treatment of optic neuritis and its use. | |
US8349312B2 (en) | Proline substituted cyclosporin analogues | |
US8236778B2 (en) | Synergistic 5′-methylthioadenosine combinations | |
US8685917B2 (en) | Cyclosporin analogues | |
US20130345148A1 (en) | Prevention and treatment of ocular side effects with a cyclosporin | |
US10610565B2 (en) | Prevention and treatment of ocular side effects with a cyclosporin | |
US20140011750A1 (en) | Prevention and treatment of ocular side effects with a cyclosporin | |
US20140011752A1 (en) | Prevention and treatment of ocular side effects with a cyclosporin | |
US9669095B2 (en) | Cyclosporin analogues for preventing or treating hepatitis C infection | |
US8906853B2 (en) | [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection | |
WO2013148155A1 (en) | Compositions and methods for the treatment of dry eye disease | |
JPH0296521A (en) | Remedy for immune disease | |
AU2013200652A1 (en) | Cyclosporin analogues for preventing or treating hepatitis C infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALLERGAN, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FEINERMAN, GREGG;BARTH, NEIL;SCHIFFMAN, RHETT M.;AND OTHERS;SIGNING DATES FROM 20060911 TO 20061019;REEL/FRAME:034760/0393 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: SAINT REGIS MOHAWK TRIBE, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLERGAN, INC.;REEL/FRAME:043830/0446 Effective date: 20170908 |